Biomedical Innovation Real Estate

Life Science, Biotechnology & Wet Lab Real Estate Financing

BancorpOne arranges debt financing for life science research campuses, biotechnology wet lab facilities, pharmaceutical cleanrooms, and biomedical incubator buildings. Concentrated in major biotech innovation clusters, life science properties require specialized mechanical infrastructure, redundant HVAC systems, and heavy capital investments that qualify for specialized institutional real estate debt.

Indicative Underwriting Matrix

Target Advance Rate Up to 65% – 70% LTV Higher leverage on long-term credit pharma leases
Minimum Target DSCR 1.25x – 1.35x Based on credit-backed biotech rental income
HVAC Air Changes 100% Outside Air (6–10 ACH) Single-pass dedicated air handling systems required
Floor-to-Ceiling Clear 14 – 16+ Feet Floor-to-Deck Accommodates complex mechanical ducting and piping
Structural Floor Load 100 – 150+ Lbs/Sq Ft Engineered for heavy analytical centrifuges and imaging
Recourse Execution Non-Recourse Options Available Available for institutional sponsors and stabilized clusters

All debt sizing metrics, tenant improvement reserves, and loan structures are underwritten by commercial capital providers based on cluster vacancy, tenant venture funding, and lab infrastructure specifications.

Specialized Infrastructure and Underwriting of Wet Lab Properties

Life science and biotechnology real estate cannot be underwritten like traditional commercial office buildings. Wet lab facilities require specialized building infrastructure that costs $200 to $400+ per square foot above standard office finishes, including single-pass 100% outside air handling units, dedicated chemical fume hood exhausts, lab-grade acid neutralization basins, and vibration-isolated structural slabs.

Commercial lenders look favorably upon life science assets located within established biomedical ecosystems with strong venture capital pipelines and top-tier research universities. BancorpOne acts as a commercial mortgage broker, placing debt through institutional lenders that recognize the high capital investment made by biotech tenants and the sticky, long-term nature of pharmaceutical research leases.

  • Tenant Capitalization & Cash Runway: Lenders evaluate biotech tenant balance sheets, clinical trial phases (Phase I/II/III), and venture funding commitments to assess rental payment certainty.
  • Wet Lab vs Dry Office Ratios: Properties with a 50/50 or 60/40 wet lab to dry office ratio command superior liquidity from institutional debt funds compared to converted office buildings with inadequate mechanical drops.
  • Hazardous Waste & Environmental Review: Lenders verify state biosafety containment ratings (BSL-1, BSL-2) and compliant biomedical waste handling manifests.
Direct Underwriting Intelligence

Frequently Answered Financing Questions

Verified answers to common borrower and broker inquiries regarding loan sizing, guidelines, and execution.

Infrastructure Requirements

What physical infrastructure do lenders look for in life science wet lab buildings?

Lenders look for 14–16+ foot floor-to-ceiling heights, 100–150 lbs/sq ft floor load capacities, 100% single-pass outside air handling systems, and centralized acid neutralization tanks.

These heavy mechanical specifications are mandatory for chemical and biological research; buildings lacking these features face severe re-tenanting obsolescence.

Review Lab Due Diligence Checklist →
Capital Advisory

Can BancorpOne arrange debt to convert traditional office buildings into wet labs?

Yes. BancorpOne structures substantial office-to-lab conversion bridge loans, providing capital to upgrade electrical services, add rooftop HVAC chillers, and build speculative lab suites.

We connect developers with institutional bridge funds experienced in funding heavy capital expenditures in primary life science submarkets.

Speak to Life Science Advisor →

Related Debt Programs & Real Estate Financing